Cargando…

ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21

Clinically, patients with urothelial carcinoma of the bladder (UCB) with tumor metastasis are incurable. To find new therapeutic strategies, the mechanisms underlying UCB invasion and metastasis should be further investigated. In this study, zinc finger and homeobox 3 (ZHX3) was first screened as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Minhua, Wei, Wensu, Duan, Jinling, Chen, Rixin, Wang, Ning, He, Leye, Peng, Yulu, Ma, Xiaodan, Wu, Zeshen, Liu, Jianye, Li, Zhiyong, Zhang, Zhiling, Jiang, Lijuan, Zhou, Fangjian, Xie, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088937/
https://www.ncbi.nlm.nih.gov/pubmed/33440047
http://dx.doi.org/10.1111/cas.14810
_version_ 1783686942590763008
author Deng, Minhua
Wei, Wensu
Duan, Jinling
Chen, Rixin
Wang, Ning
He, Leye
Peng, Yulu
Ma, Xiaodan
Wu, Zeshen
Liu, Jianye
Li, Zhiyong
Zhang, Zhiling
Jiang, Lijuan
Zhou, Fangjian
Xie, Dan
author_facet Deng, Minhua
Wei, Wensu
Duan, Jinling
Chen, Rixin
Wang, Ning
He, Leye
Peng, Yulu
Ma, Xiaodan
Wu, Zeshen
Liu, Jianye
Li, Zhiyong
Zhang, Zhiling
Jiang, Lijuan
Zhou, Fangjian
Xie, Dan
author_sort Deng, Minhua
collection PubMed
description Clinically, patients with urothelial carcinoma of the bladder (UCB) with tumor metastasis are incurable. To find new therapeutic strategies, the mechanisms underlying UCB invasion and metastasis should be further investigated. In this study, zinc finger and homeobox 3 (ZHX3) was first screened as a critical oncogenic factor associated with poor prognosis in a UCB dataset from The Cancer Genome Atlas (TCGA). These results were also confirmed in a large cohort of clinical UCB clinical samples. Next, we found that ZHX3 could promote the migration and invasion capacities of UCB cells both in vitro and in vivo. Mechanistically, coimmunoprecipitation (coIP) and mass spectrometry (MS) analysis indicated that ZHX3 was a target of tripartite motif 21 (TRIM21), which mediates its ubiquitination, and subsequent degradation. Notably, RNA‐seq analysis showed that ZHX3 repressed the expression of regulator of G protein signaling 2 (RGS2). Generally, our results suggest that ZHX3 plays an oncogenic role in UCB pathogenesis and might serve as a novel therapeutic target for UCB.
format Online
Article
Text
id pubmed-8088937
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80889372021-05-10 ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21 Deng, Minhua Wei, Wensu Duan, Jinling Chen, Rixin Wang, Ning He, Leye Peng, Yulu Ma, Xiaodan Wu, Zeshen Liu, Jianye Li, Zhiyong Zhang, Zhiling Jiang, Lijuan Zhou, Fangjian Xie, Dan Cancer Sci Original Articles Clinically, patients with urothelial carcinoma of the bladder (UCB) with tumor metastasis are incurable. To find new therapeutic strategies, the mechanisms underlying UCB invasion and metastasis should be further investigated. In this study, zinc finger and homeobox 3 (ZHX3) was first screened as a critical oncogenic factor associated with poor prognosis in a UCB dataset from The Cancer Genome Atlas (TCGA). These results were also confirmed in a large cohort of clinical UCB clinical samples. Next, we found that ZHX3 could promote the migration and invasion capacities of UCB cells both in vitro and in vivo. Mechanistically, coimmunoprecipitation (coIP) and mass spectrometry (MS) analysis indicated that ZHX3 was a target of tripartite motif 21 (TRIM21), which mediates its ubiquitination, and subsequent degradation. Notably, RNA‐seq analysis showed that ZHX3 repressed the expression of regulator of G protein signaling 2 (RGS2). Generally, our results suggest that ZHX3 plays an oncogenic role in UCB pathogenesis and might serve as a novel therapeutic target for UCB. John Wiley and Sons Inc. 2021-03-09 2021-05 /pmc/articles/PMC8088937/ /pubmed/33440047 http://dx.doi.org/10.1111/cas.14810 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Deng, Minhua
Wei, Wensu
Duan, Jinling
Chen, Rixin
Wang, Ning
He, Leye
Peng, Yulu
Ma, Xiaodan
Wu, Zeshen
Liu, Jianye
Li, Zhiyong
Zhang, Zhiling
Jiang, Lijuan
Zhou, Fangjian
Xie, Dan
ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21
title ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21
title_full ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21
title_fullStr ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21
title_full_unstemmed ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21
title_short ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21
title_sort zhx3 promotes the progression of urothelial carcinoma of the bladder via repressing of rgs2 and is a novel substrate of trim21
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088937/
https://www.ncbi.nlm.nih.gov/pubmed/33440047
http://dx.doi.org/10.1111/cas.14810
work_keys_str_mv AT dengminhua zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT weiwensu zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT duanjinling zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT chenrixin zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT wangning zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT heleye zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT pengyulu zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT maxiaodan zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT wuzeshen zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT liujianye zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT lizhiyong zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT zhangzhiling zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT jianglijuan zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT zhoufangjian zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21
AT xiedan zhx3promotestheprogressionofurothelialcarcinomaofthebladderviarepressingofrgs2andisanovelsubstrateoftrim21